Telix Pharmaceuticals Hosts Investor Day in New York City

An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals Limited is hosting an Investor Day event in New York City, which will be a hybrid event allowing both in-person and virtual participation. This event is significant for stakeholders as it provides an opportunity for institutional investors and analysts to engage with the company, potentially impacting Telix’s market positioning and investor relations.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company is headquartered in Melbourne, Australia, and operates internationally in the United States, Brazil, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology and rare diseases.

Average Trading Volume: 1,601,190

Technical Sentiment Signal: Buy

Current Market Cap: A$8.79B

For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.